If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
291
results.
Updated on
15/07/2026 [08:14:00]
Results 100 to 125 of 291
Absstract of: WO2026125700A1
The invention relates to the treatment of triple negative breast cancer (TNBC) with an activator of mTOR (Mammalian Target of Rapamycin). It has been found that migration of TNBC cells is significantly inhibited by an activation of mTOR, in particular of mTORC1, so that the early steps of metastasis, i.e. the migration in the microenvironment of the tumour, can be addressed in a targeted manner. The treatment according to the invention is preferably accompanied by chemotherapy or immunotherapy.
Absstract of: WO2021048619A2
The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure turther provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment
Absstract of: WO2026128628A1
The present disclosure is related to non-destructive, long-term electrophysiological recording and stimulation of organoids. For example, an example device includes biocompatible material and electrodes fabricated onto the biocompatible material. The example device, through controlled buckling and microfolding, forms a pocket for an organoid.
Absstract of: WO2025031900A1
The present invention relates to a human ectoderm derived brain cell characterized by the following features: (1) the intron between exons 10 and 11 of the MAPT gene encoding the Tau protein has been removed by genome-editing from one or both allele(s); and (2) at least one of the alleles of the MAPT gene of (1) carries at least one mutation enhancing Tau aggregation and at least one mutation enhancing nucleation of Tau aggregation; or (3) one allele of the MAPT gene as defined in claim 1(1) carries at least one mutation enhancing Tau aggregation, preferably in exon 10, and the other allele carries at least one mutation enhancing nucleation of Tau aggregation, preferably in exon 11.
Absstract of: WO2025032070A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Absstract of: WO2024258222A1
The present invention relates to: a composition and system for predicting or diagnosing hearing loss disorders, the composition including an agent for detecting point mutations in a plurality of genes or copy number variations; and an information provision method. In an aspect, the present invention comprises an agent capable of detecting: point mutations in a plurality of genes; or a copy number variation of at least one gene selected from the group consisting of STRC and TOOTA, thereby enabling simultaneous screening of a plurality of mutations on the basis of real-time PCR instead of NGS, thus having an excellent effect of predicting or diagnosing hearing loss in a short time at a low cost.
Absstract of: CN122218243A
0001 本发明涉及临床及分子生物学领域，具体提供载脂蛋白E（APOE）作为睾丸Leydig细胞衰老的标记物的应用。本发明首次发现并证实，APOE在人和小鼠睾丸Leydig细胞中特异性表达，且其表达水平随年龄增长而显著上调，与Leydig细胞的衰老程度呈正相关。更重要的是，APOE虽不诱导典型的细胞衰老表型（如SA‑β‑gal活性增加），但能显著影响Leydig细胞内的脂滴积累，并正向调控睾酮的合成能力。临床数据显示，血清APOE浓度与多种性激素水平呈显著负相关。此外，在衰老阶段，APOE基因敲除（APOE‑KO）小鼠表现出生精障碍和Leydig细胞脂滴减少，其机制与胆固醇代谢通路紊乱密切相关。
Absstract of: WO2025117965A1
The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.
Absstract of: WO2025110434A1
The present application relates to a cerebral microbleed animal model in which cerebral microbleeds are induced by Col4a1-targeting guide RNA (gRNA) packed with AAV-BR1.
Absstract of: WO2025101127A1
The disclosure concerns conjugated oligoelectrolytes as represented by Formula (I) and their methods of use thereof. The conjugated oligoelectrolytes are suitable for use to stain mitochondria.
Absstract of: WO2024251257A1
Provided are antibodies or fragments thereof having binding specificity to the human CD24 protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating cancer are also provided.
Absstract of: CN122218240A
本申请涉及血液p‑tau 217和GFAP标志物联用在制备阿尔茨海默病检测的辅助诊断试剂中的应用。该应用中，利用p‑tau 217检测试剂检测待测样本中p‑tau 217的水平，利用GFAP检测试剂检测待测样本中GFAP的水平；当p‑tau 217检测项目和GFAP检测项目的检测水平与其对应参考水平的关系均满足设定条件时，判定为符合条件，不对受检者进行进一步的PET影像学检查或脑脊液检查；否则，对受检者进行进一步的PET影像学检查或脑脊液检查。本申请技术方案，能够提升AD的辅助排查检测的准确率，减少需要进一步做Aβ PET检查或脑脊液检查确证的患者比例，节约医疗资源，减少患者负担。
Absstract of: CN122218242A
本发明提供了一组血浆蛋白质复合标志物在评估器官衰老程度中的方法和应用。具体地，本发明提供了蛋白质复合标志物在评估器官衰老程度和构建器官蛋白质时钟中的用途，以及评估器官衰老程度的方法；其中，所述蛋白质复合标志物共计使用494种血浆蛋白质，可同时评估全身、心血管、肝脏、免疫系统、代谢系统、肌肉骨骼、肺、肾脏、全脑、灰质、白质、功能性连接脑区的衰老状态。研究表明，利用本发明的蛋白质复合标志物进行器官衰老评估和患病风险预测的方法或系统准确性好且灵敏度高，具有大规模临床应用的前景。
Absstract of: CN122213992A
0001 本发明涉及一种基于碳点@共价有机框架的光阴极材料及其制备方法和应用，属于光电化学生物传感器技术领域。一种基于碳点@共价有机框架的光阴极材料，所述光阴极材料为原位生长于导电基底上的CDs@T‑D‑COF薄膜，所述CDs@T‑D‑COF薄膜中碳点均匀分布于由TAPA与DHNDA缩合形成的COF孔道中。此外，本发明基于CDs@T‑D‑COF构建了一种可精准识别人血浆中痕量Aβ42的光电化学免疫传感器阵列，其在灵敏度、特异性和实用性方面均实现显著突破，尤其适用于复杂生物基质中极低浓度标志物的可靠检测，在临床转化应用中展现出广阔前景。
Absstract of: CN122214280A
本发明涉及一种分泌维生素B3单克隆抗体的杂交瘤细胞株及其应用，属于免疫检测技术领域。本发明经过多次筛选获得了一种能够分泌维生素B3单克隆抗体的杂交瘤细胞株，本发明的杂交瘤细胞株分泌的维生素B3单克隆抗体对维生素B3具有优异的亲和力和灵敏度，对维生素B3的IC50达到14.36 ng/mL，且对于维生素B3的结构类似物，例如维生素A、维生素K2、维生素K3、维生素K4、维生素E均无交叉反应。因此本发明的单克隆抗体可用于制备维生素B3的免疫检测产品，为维生素B3的残留检测提供高效的检测方法及手段。
Absstract of: CN122218228A
0001 本发明涉及生物医药技术领域，具体公开了唾液TP17、TP47、TP15特异性抗体在制备神经梅毒辅助诊断产品中的应用。基于唾液中梅毒螺旋体特异性抗体免疫球蛋白G（IgG），包括唾液TP17/IgG、TP47/IgG和TP15/IgG的联合检测，输出受检者发生神经梅毒的风险值，或联合血清TRUST滴度构建四联合Logistic回归判别模型，基于预设判定阈值对受检者进行低风险或高风险分层，从而提高对神经梅毒的综合识别能力。本发明采用唾液作为检测样本，具有无创、便捷、易推广、可重复采集等优点，可用于神经梅毒的早期筛查、辅助诊断、及临床路径管理。
Absstract of: WO2024206667A1
The disclosure provides systems and methods for detecting anti-NMDAR autoantibody based on the strong affinity of anti-NMDAR autoantibodies to a plurality of non-randomized anti-NR1 coupled to a solid support. The disclosure further provides therapeutic methods for an anti-NMDAR pathology by a therapeutic anti-NMDAR antibody, ART5803. The disclosure further provides methods and systems for screening and predicting the potential responsiveness to ART5803 treatment.
Absstract of: WO2022013286A1
A method for detecting p217+tau in blood-based samples from a subject with high sensitivity, accuracy, and precision. The assay comprises contacting a sample with a capture antibody directed against a p217+tau epitope to bind the capture antibody to p217+tau peptides in plasma to form antibody-peptide complexes, and separately contacting the antibody-peptide complexes with a detection antibody to bind the detection antibody to the antibody-peptide complexes. The amount of p217+tau is determined by detecting the detection antibody. The amount of p217+tau detected is used to determine whether the subject has tauopathy or is at risk of developing tauopathy, or whether the subject has amyloidogenic disease or is at risk of developing amyloidogenic disease when the amount of p217+tau peptides is above a predetermined threshold value. The method has improved sensitivity such that the predetermined threshold value is above a Lower Limit of Quantification and/or Lower Limit of Detection of the assay.
Absstract of: CN122193589A
0001 本发明提供了一种阿尔茨海默症患者尿液中的相关性蛋白检测方法及其应用，涉及生物医药领域，检测方法包括：取预制有荧光微球标记的蛋白抗体2和磁颗粒标记的蛋白抗体1的反应管；将尿液样本加入到反应管中；向反应管中加入尿液稀释液，混匀后室温放置，反应8‑12小时；使用磁铁富集免疫复合物，用紫光照射复合物，判断复合物荧光强度。通过利用一对配对的抗体（捕获抗体与检测抗体）特异性抓取尿液中的超低浓度靶蛋白，通过磁珠将其从复杂基质中拾取并浓缩，再借助高亮度荧光微球将生物识别事件转化为强烈的光信号，最终通过肉眼或仪器实现定性或定量检测，进而实现对尿液中相关性蛋白进行检测的目的，降低了操作门槛和经济成本。
Absstract of: CN122187963A
0001 本发明涉及一种靶向β‑淀粉样蛋白的纳米抗体及其应用。所述纳米抗体的CDR1的氨基酸序列包括SEQ ID NO.1或与SEQ ID NO.1具有至少80％同一性的序列，CDR2的氨基酸序列包括SEQ ID NO.2或与SEQ ID NO.2具有至少80％同一性的序列，CDR3的氨基酸序列包括SEQ ID NO.3或与SEQ ID NO.3具有至少80％同一性的序列。本发明设计制备全新的靶向β‑淀粉样蛋白的纳米抗体，能够靶向和结合多种形式Aβ蛋白，具备高亲和力，可有效应用于β‑淀粉样蛋白的检测以及AD的诊断和治疗等领域，同时具备合成成本低、性质稳定等优点，利于推广应用。
Absstract of: CN122188000A
0001 本发明提供一种262位点磷酸化的Tau蛋白、其制备方法与应用，属于生物工程技术领域，本发明提供的262位点磷酸化的Tau蛋白的制备方法，包括以下步骤：S1：合成SEQ ID No.1所示的多肽序列，SEQ ID No.1：KSKIGSTENLKHCC，其中，SEQ ID No.1的第六位氨基酸为磷酸化丝氨酸；S2：偶联Tau蛋白和SEQ ID No.1所示的多肽，反应后获得262位点磷酸化的Tau蛋白。通过本发明提供的制备方法，可以完全避免非特异性过度磷酸化的问题，同时，提供上述制备方法制得的262位点磷酸化的Tau蛋白具有较高的结合效率和稳定性。
Absstract of: CN122193590A
本申请涉及一种用于评估或诊断多系统萎缩患者的血液生物标志物及其用途。其中的血液生物标志物为α‑Syn、NfL中至少一种与C3的组合。通过该血液生物标志物，能够辅助多系统萎缩患者的早期诊断和连续监测，检测成本低、操作简单、检测速度快、创伤性小、可及性好，适合大多数患者使用，临床应用价值高。
Absstract of: WO2025059487A2
The present disclosure provides cell penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human beta amyloid and methods of using these cell penetrating agents to treat patients with beta amyloid related diseases, including Inclusion-body myositis (IBM).
Absstract of: CN122187969A
0001 本发明涉及一种神经生长因子特异性抗体及其制备方法用途。本发明提供的抗体可以特异性识别检测重组人神经生长因子突变体，不结合人神经生长因子前体蛋白和/或野生型人神经生长因子及其前体蛋白，在重组人神经生长因子突变体的检测中具有良好的应用前景。
Nº publicación: CN122206940A 12/06/2026
Applicant:
贝克曼库尔特有限公司
Absstract of: WO2025101478A1
The presently claimed and described technology provides methods for detecting phosphorylated tau (p-tau)217 in a biological sample using an immunoassay analyzer.
BOPI
Electronic site
